Showing results (1-10 of 153) with videos related to
Sort By:
Pageof 16
Nature Reviews. Clinical Oncology|June 10, 2020
The adenosine pathway in immuno-oncologyBertrand Allard, David Allard, Laurence Buisseret, et al.Nature Reviews. Clinical Oncology|July 19, 2020
Publisher Correction: The adenosine pathway in immuno-oncologyBertrand Allard, David Allard, Laurence Buisseret, et al.Oncoimmunology|August 16, 2019
Adenosine A2a receptor promotes lymphangiogenesis and lymph node metastasisBertrand Allard, Isabelle Cousineau, David Allard, et al.Cancer Research|November 23, 2016
PolyI:C and CpG Synergize with Anti-ErbB2 mAb for Treatment of Breast Tumors Resistant to Immune Checkpoint InhibitorsRoxanne Charlebois, Bertrand Allard, David Allard, et al.Methods in Molecular Biology (Clifton, N.J.)|September 2, 2016
Methods to Evaluate the Antitumor Activity of Immune Checkpoint Inhibitors in Preclinical StudiesBertrand Allard, David Allard, John StaggJournal for Immunotherapy of Cancer|February 27, 2020
On the mechanism of anti-CD39 immune checkpoint therapyDavid Allard, Bertrand Allard, John StaggSeminars in Immunology|October 13, 2019
Targeting the adenosine pathway for cancer immunotherapyAkil Hammami, David Allard, Bertrand Allard, et al.Methods in Molecular Biology (Clifton, N.J.)|December 31, 2022
Assessing the Efficacy of Immune Checkpoint Inhibitors in Preclinical Tumor ModelsCelia Jacoberger-Foissac, Bertrand Allard, David Allard, et al.Immunology Letters|May 15, 2018
Targeting the CD73-adenosine axis in immuno-oncologyDavid Allard, Pavel Chrobak, Bertrand Allard, et al.Immunotherapy|January 26, 2016
CD73-adenosine: a next-generation target in immuno-oncologyDavid Allard, Bertrand Allard, Pierre-Olivier Gaudreau, et al.Pageof 16